title: Different involvement of ventral and dorsal norepinephrine pathways on norepinephrine reuptake inhibitor-induced locomotion and antidepressant-like effects in rats.
abstract: Two experiments were performed to investigate the involvements of ventral and dorsal norepinephrine bundle (VNB and DNB) in a selective norepinephrine reuptake inhibitor (NRI) reboxetine (RBX)-induced locomotion and antidepressant-like effects. Rats in the Experiment 1 received a local brain injection of 6-hydroxydopamine (6-OHDA) or an intraperitoneal injection of N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) to lesion their VNB or DNB, respectively. Acute effects of RBX (10 mg/kg, i.p.) on the locomotor activity and the forced swim test (FST) were measured 14 days after the lesion. In Experiment 2, activities of the norepinephrine transporter (NET) and the protein kinase C (PKC) in cortex, hippocampus, and locus coeruleus (LC) were detected by western blot after 14 days chronic RBX treatment. Results showed that the antidepressant-like effect of RBX was blocked in VNB lesion but augmented in DNB lesion, and was not relevant to the RBX-induced hypoactivity. Fourteen-days RBX treatment altered the activities of NET and PKC in LC but not hippocampus or cortex. The possible involvement of VNB and DNB in the RBX-induced antidepressant-like effect is discussed.
authors.affiliation: Department of Psychiatry, Beitou Armed Forces Hospital, Taipei, Taiwan.
authors.forename: Yu-Chi
authors.initials: YC
authors.lastname: Ku
authors.forename: Ya-Ju
authors.initials: YJ
authors.lastname: Tsai
authors.forename: Che-Se
authors.initials: CS
authors.lastname: Tung
authors.forename: Tien-Haw
authors.initials: TH
authors.lastname: Fang
authors.forename: Shih-Mao
authors.initials: SM
authors.lastname: Lo
authors.forename: Yia-Ping
authors.initials: YP
authors.lastname: Liu
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001522:Behavior, Animal / Q000187:drug effects; D002540:Cerebral Cortex / Q000187:drug effects / Q000378:metabolism; D003863:Depression / Q000188:drug therapy* / Q000378:metabolism; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism; D008125:Locus Coeruleus / Q000187:drug effects / Q000378:metabolism; D008297:Male; D009025:Morpholines / Q000494:pharmacology*; D009043:Motor Activity / Q000187:drug effects*; D009434:Neural Pathways / Q000187:drug effects / Q000378:metabolism; D009638:Norepinephrine / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D000077593:Reboxetine; D013550:Swimming
chemical_list: D018759:Adrenergic Uptake Inhibitors; D000928:Antidepressive Agents; D009025:Morpholines; D000077593:Reboxetine; D009638:Norepinephrine